Why we need a body to oversee how science is used by governments

Science and Politics Ian Boyd Polity (2024)Say what you really think, Sir Ian. Politics attracts people who are comfortable with “lying” and “manufacturing social truth” and who “do not distinguish between fantasy and reality”, Ian Boyd notes in his book Science and Politics. Moreover, many scientists are falling “for the wisdom of crowds”, “following the money” or, worse, indulging in the “evil” of normative research by designing studies to confirm their preferences. Borrowing former US president Barack Obama’s scathing comment about lawyers, the author labels many of those researchers as “highly credentialed, high-IQ morons”.AI tools as science policy advisers? The potential and the pitfallsIn short, I loved this book. In Science and Politics, Boyd — an ecologist and former adviser to the UK government — weaves together anecdote and reason to unpick the “troubled marriage” between research and government. He offers insights into life inside the “policy factory” as a participant and, frequently, a frustrated observer. His narrative never shies away from robust language, yet it somehow retains an upbeat tenor throughout.The relationship between science and politics is, Boyd laments, “too much theory and too little practice”. Boyd is very much a practitioner of science advice, having spent seven years (2012–19) as chief scientific adviser at the UK Department for Environment, Food and Rural Affairs (Defra). He also had a key role in developing science-advisory structures during the COVID-19 pandemic.I overlapped with Boyd’s tenure at Defra while I was leading the Parliamentary Office of Science and Technology, the UK Parliament’s in-house source of research analysis. For years, I asked science and policy researchers how we could provide better advice, but the answers were rarely useful. This book, with its shamelessly practical bent, would have helped a lot.There’s much in here, too, that tallies with my current role as a practice-focused academic who helps executives and legislatures to improve their use of evidence in decision making. Government clients usually ask me how they should design systems and processes. Although that is important, my starting point focuses on how to improve institutional cultures and the quality of staff.How to spend one trillion dollars: the US decarbonization conundrumBoyd agrees, and shares example after example of how, in the UK government, the truth is too often considered toxic and politicians and civil servants are unqualified or unable to hear it. For example, one senior civil servant told him how it was their job “to keep science advisers in their ‘boxes’”. Boyd recalls the “horror” on one UK cabinet minister’s face when he tried to explain something in theoretical terms.While acknowledging flaws in the system, Boyd notes the benefits of the UK model of having chief scientific advisers in each ministry — individuals who are responsible for bringing research evidence to bear on policy. It won’t work when there is a bad adviser in the post, but a good one can be very effective at honing policy options, identifying unintended consequences and stopping bad ideas.The rise of AI in policyLooking to the future, Boyd flags how artificial intelligence (AI) promises to alter the functioning of government institutions. For example, ‘digital twins’ are increasingly used to test policy options. These are computer models that mimic complex systems associated with, for instance, agriculture, ecology or public health.AI tools will also put evidence scoping and synthesis into the hands of mainstream policymakers, an advance that will surely be a headache for science advisers (see C. Tyler et al. Nature 622, 27–30; 2023). It is easy to imagine how political figures might use AI tools to produce ‘policy-based evidence’ rather than ‘evidence-based policy’.Until now, advisers have been responsible for delivering or contextualizing scientific evidence and understanding its nuances. This isn’t always easy, or popular. For example, Boyd reflects on how he was politically exposed for having to explain weaknesses in opposing evidence syntheses on the role of badgers in the spread of bovine tuberculosis. In a room filled with the most senior politicians, civil servants and the president of the farming union, Boyd overruled approvals for two badger culls, which led to “an embarrassing climb-down by the politicians”.Badgers can be vaccinated against bovine tuberculosis as an alternative to culling them.Credit: NPL/AlamyBecause AI tools make more-advanced modes of decision-making more attainable — such as real-time policy testing that produces feedback leading to better outcomes — advisers will need to increase their monitoring efforts to maintain the standards of people who use science but who are not trained in it.How can scientific rigour be maintained? Boyd recommends establishing a science office, modelled on the UK Office for National Statistics or the UK Office for Budget Responsibility, that holds policymakers and science advisers to account in their use of research. This is not a new idea, but it is the most high-profile argument I have seen for it so far.Such a statutory authority would enforce a system of internationally accepted standards, such as “follow the guidance of science” and “formally state your reasoning if you choose to depart from that guidance”. The latter part exists in several documents, including the UK ministerial code. Debate over upholding these standards will be lively, but resolvable.Decision makers need constantly updated evidence synthesisYet Boyd feels that the current guidance lacks teeth. He professes to feeling “coercion to conform to the current political will” and feared a “dark space” where he could “control policies by tilting the ‘evidence’”. He argues that it would have been preferable, as a scientist working in policy, to be responsible to an external authority.Serious thought would be required to ensure that a scientific authority does not seem to be a form of technocracy aimed at overturning democracy. Boyd suggests a renewed commitment to “open science” and “scientific freedoms” and calls for making the scientists of this body visible. In my view, such a body would also do well to adopt modes of social-scientific research that involve public participation.After finishing Science and Politics, and despite its horror stories about the peddling of “hocus-pocus” by “charlatans”, I still felt upbeat. Boyd reflects that bringing science to bear on policymaking is important because there is societal value in “merging reality with aspiration”. This is an apt description of this book and a fabulous summary of Boyd’s career.

Tackling Europe’s antimicrobial resistance problem with QuantaMatrix’s technologies

Antimicrobial resistance (AMR) is becoming one of the biggest health and societal threats today. Recognising the severity of this problem, clinical microbiology company Quantamatrix has developed innovative technologies to help tackle the issue.The issue of antimicrobial resistance poses a threat not only to individual health but also to the safety of society as a whole. Resistant bacteria can spread between individuals, crossing borders and proliferating globally, potentially leading to large-scale outbreaks akin to a ‘pandemic’, which places a tremendous burden on public health systems.
The World Health Organization (WHO) refers to AMR as a ‘silent pandemic’ and has classified it as one of the top ten threats to global public health. According to the international medical journal The Lancet, more than one million people have died each year from drug-resistant infections as a direct cause of death between 1990 and 2021, with projections suggesting that this number could reach two million annually by 2050. Additionally, the UK’s antimicrobial resistance report by Jim O’Neill warns that, if AMR is not adequately addressed, the number of direct and indirect deaths from AMR could exceed ten million worldwide by 2050, surpassing the eight million deaths caused by cancer.
Reasons for AMR and the global issue of AMR: The One Health Initiative
The primary cause of AMR is the misuse and overuse of antimicrobials. For instance, during the pandemic, antimicrobials, antifungals, and AR antimicrobials were indiscriminately used on COVID-19 patients, despite their ineffectiveness against the virus, exacerbating the AMR problem. Additionally, as medical facilities, resources, and personnel were concentrated on responding to COVID-19, infection prevention, surveillance, control, and appropriate treatment for potential AMR patients weakened, leading to an increase in antimicrobial-resistant bacteria.
Particularly concerning is the continuous rise of antimicrobial-resistant pathogens known as ‘superbugs’, which are no longer responsive to antimicrobials, viruses, fungi, and parasites, further deepening the AMR crisis.
To address this AMR issue, the global initiative known as ‘One Health’ has been launched. One Health aims to tackle the worldwide AMR problem through a four-part collaboration involving the World Health Organization (WHO), the Food and Agriculture Organization (FAO), the World Organisation for Animal Health (WOAH), and the United Nations Environment Programme (UNEP). In a new declaration made during the UN high-level meeting on AMR in September, it was pledged to reduce deaths caused by AMR by 10% over the next six years, in response to the ‘silent slow-motion pandemic’ that could claim around 39 million lives by 2050.
Moreover, the initiative recognises the close interconnection between human health, animal health, and the environment, emphasising the need to strengthen strategic co-operation at local, national, and global levels regarding not only human and animal health but also food security, environmental issues, and economic concerns.
Antimicrobial resistance issues in Europe
In the European Union (EU) and the European Economic Area (EEA), the costs associated with antimicrobial resistance were estimated to reach approximately €1.5bn annually as of 2022. In 2022 alone, over 35,000 people died from drug-resistant bacterial infections in Europe. This figure surpasses the combined death toll from influenza, tuberculosis, and HIV/AIDS, indicating that if the spread of resistant bacteria continues, it could have severe repercussions not only on public health systems but also across society as a whole.
However, the EU lags behind the United States, China, the United Kingdom, India, and Australia in the field of AMR research. Even Germany, which has published the most papers in the EU, has only around 6,000 publications, which is half the number of those from the UK or India. Furthermore, none of the top ten institutions in antimicrobial resistance research are located within the EU, suggesting a relatively low concentration of AMR research in the region.
Importance of rapid diagnostics in overcoming AMR
In the medical field directly addressing the AMR issue, close collaboration among healthcare professionals, industry, and government is essential to overcome this challenge. Stabilising the supply chain for existing antimicrobials, developing new antimicrobials, and implementing ‘rapid diagnostics’ to prevent the misuse of antimicrobials are all crucial.
Particularly when bacterial bloodstream infections progress to sepsis, the survival rate declines sharply by 7-9% per hour after onset, leading to a 30% mortality rate within 30 days. Current diagnostic methods often involve the empirical use of broad-spectrum antimicrobials, which can take a long time to identify the optimal antimicrobial treatment, thereby accelerating the problem of antimicrobial resistance and threatening patient lives.
Therefore, rapid and accurate diagnostics are vital, as timely treatment with the correct antimicrobials can significantly impact patient outcomes. Recognising this need early on, the innovative company in clinical microbiology, Quantamatrix, has developed dRAST™ and uRAST to achieve faster and more accurate diagnostics.
Quantamatrix and dRAST™
Quantamatrix was established in 2010 as a spin-off from the laboratory of Professor Kwon Sung-hoon in the Department of Electrical Engineering at Seoul National University, South Korea. CEO Kwon founded the company with the goal of developing innovative platforms in clinical microbiology and molecular/immunodiagnostics to save patients’ lives through early diagnosis and improve healthcare environments.
In 2016, Quantamatrix developed the dRAST solution (direct & Rapid Antimicrobial Susceptibility Testing), which revolutionised the field of clinical microbiological diagnostics. While traditional antimicrobial susceptibility testing (AST) typically takes about 60 hours, dRAST significantly reduces this testing time by 30 to 50 hours, allowing for quicker and more effective treatment decisions.
Fig. 1: dRAST work flow
Three core proprietary technologies of dRAST
The rapid diagnostic capability of dRAST is attributed to three core proprietary technologies:

Microfluidics and bacterial immobilisation technology: This technology allows for the effective mixing of positive blood culture samples with agarose, which is then dispensed onto a chip and gelled to immobilise the bacteria within a thin layer of agarose.
Microscopic imaging: dRAST employs advanced microscopic imaging techniques to capture time-series images of bacterial growth. This allows for real-time monitoring of bacterial activity.
AI-driven big data analysis: Using algorithms trained through artificial intelligence (AI), dRAST can quickly assess bacterial growth or non-growth based on the imaging data. Traditional antimicrobial susceptibility testing (AST) methods, used globally for over 30 years, primarily relied on turbidity changes due to metabolic activity when bacteria encounter antimicrobials, which required waiting for physical metabolic processes and thus took a long time. In contrast, dRAST conducts AST directly from positive blood cultures, determining the effectiveness of antimicrobials within five to seven hours.

dRAST is optimised for testing both Gram-positive and Gram-negative bacteria, offering advantages in daily testing capacity, antimicrobial diversity, concentration composition for each antimicrobial, ease of use, and convenient reagent storage, making it a comprehensive rapid diagnostic solution.
Fig. 2: Three core proprietary technologies of dRAST
dRAST’s global market penetration
dRAST was commercialised for the first time in the world at Seoul National University Hospital in South Korea in 2019. Following this, the same year, Quantamatrix established its European subsidiary in Paris, France, to directly target the global market. They have secured over 50 customer hospitals in key countries, including Germany, the UK, France, and Switzerland, as well as in Spain, Portugal, Poland, the Czech Republic, and Romania, accelerating their commercialisation efforts.
Recently, Quantamatrix has also expanded into the Middle East, entering markets in Saudi Arabia, Kuwait, Oman and the UAE, as well as Southeast Asia, further promoting market growth.
Clinical trial results of dRAST: Ramon Y Cajal
In April, at the largest European clinical microbiology and infectious diseases conference, ‘ESCMID Global 2024,’ results were presented from a study conducted over the past year at a hospital in Spain involving 300 patients, focusing on the ‘clinical and economic utility of dRAST’. The rapid test results provided by dRAST enabled prompt prescription of appropriate antimicrobials, reducing the 30-day mortality rate for severe sepsis patients from 24.4% to 9.5%, a decrease of 14.9 percentage points. For all patients with bacteremia, the 30-day mortality rate dropped from 13.5% to 9.6% with dRAST use, representing a reduction of 3.9 percentage points. This suggests that, for every 26 dRAST tests performed, one patient’s life can be saved.
Additionally, in the economic evaluation of hospital operations, a frequently used metric is the average length of stay in the intensive care unit (ICU), which decreased from 12.4 days to six days, a reduction of over six days. Quantifying this change indicates a potential direct healthcare cost savings of approximately €13,440. Reducing patient length of stay increases bed turnover, allowing hospitals to accommodate more new patients, thereby enhancing operational efficiency and expanding economic benefits. The use of dRAST not only saves lives but also demonstrates significant economic and social value.
Fig. 3: uRAST all tests completed within 13 hours
Next-generation technology, uRAST
In July, Quantamatrix developed the all-in-one rapid antimicrobial susceptibility testing technology, uRAST (ultra-Rapid Antimicrobial Susceptibility Testing), which integrates all processes before AST, completing all tests in just 13 hours. This technology was developed in collaboration with Seoul National University and Seoul National University Hospital and was introduced in July in the prestigious journal Nature (Impact factor: 64.8 in 2022).1
The ‘uRAST’ technology combines Quantamatrix’s ‘dRAST’ technology with the bacterial identification technology ‘QmapID (QuantaMatrix Multi Assay Platform IDentification),’ allowing the entire process to be completed in one day. Notably, the QmapID technology utilises a method of inscribing specific codes onto microdisks smaller than a hair cross-section, enabling the specific differentiation of 50 to 100 different bacterial species in a single test. This innovation significantly reduces the physical workload and time required for bacterial identification. Together with dRAST, the uRAST technology is regarded as an innovative solution to address the issue of AMR.
Future aspirations
Kwon Sung-hoon, CEO, stated: “After commercialising dRAST, I set a goal to innovate by integrating reverse processes such as bacterial identification and blood culture. The biggest challenge was whether we could eliminate the time-consuming blood culture process. Through dedicated research to solve this issue, we were able to develop the uRAST technology, which led to our achievements being featured in Nature.
“We aim to bring about another disruptive change with μCIA (micro Culture-Identification-AST), an integrated testing solution that commercialises the uRAST technology in the rapid AST market led by our current flagship product, dRAST. While continuously pursuing the global expansion of dRAST, we are committed to developing the all-in-one testing system μCIA to showcase yet another innovation in the field of clinical microbiology diagnostics.”
References

Blood culture-free ultra-rapid antimicrobial susceptibility testing, Nature volume 632, pages 893–902 (2024)

Please note, this article will also appear in the 20th edition of our quarterly publication.

Heckler & Koch USA MR556 A4 & MR762 A4

Heckler & Koch, the global leader in small arms, is excited to announce the release of the new MR A4 Series. The MR556 A4 and MR762 A4 are the latest products released by HK-USA.

The A4’s updated furniture and fully ambidextrous controls make it more user-friendly than ever. A new lifetime barrel bore guarantee, an HK first, reflects HK’s confidence in this no-compromise civilian product.

[embedded content][embedded content]

“Our testing has shown our proprietary cannon-grade steel barrels vastly outperform so-called mil-spec barrels in both accuracy and durability. We’re so confident in our barrels that we now guarantee them for life. You shoot it out, we’ll replace it. Period.”

Nathan Shueth, HK Director of Business Development

Schueth said HK tested the MR556 A4 head-to-head with a with a mil-spec chrome-lined barrel to compare accuracy and durability. After 12,000 rounds, the HK experienced no degradation in accuracy, while the mil-spec competitor was shooting groups 2.5X larger than its baseline.

The updated MR rifles are feature-rich and now reflect the latest technologies included in the newest models of the select-fire HK416 and HK417 they are patterned after. A few key updates include a 2-position adjustable gas block for shooting suppressed or un-suppressed, a new fully ambidextrous lower receiver (bolt catch/release, magazine release, 45-degree selector levers) and new slimline handguard and buttstock. At launch, the MR556 A4 will come in two barrel lengths: a 11.5 in. pistol configuration, and a 16.5 in. Rifle. The MR762 A4 will ship with a 16.5 in. barrel.See also

Source: Heckler & Koch news release

Jamaica sets sights on becoming global health and wellness tourism leader

Jamaica aims to be a global leader in health and wellness tourism, leveraging its cultural and natural assets to attract transformative travel experiences.

MONTEGO BAY, JAMAICA – Tourism Minister, Hon Edmund Bartlett says Jamaica is positioning itself as a global leader in health and wellness tourism, combining its rich cultural heritage and natural resources to attract travellers seeking transformative experiences.
The Minister shared this ambitious vision yesterday (November 14) at the 6th Annual Jamaica Health and Wellness Tourism Conference, held at the Montego Bay Convention Centre. The event, themed “Beyond the Horizon: Embracing Innovation in Health and Wellness Tourism,” brought together industry leaders, innovators, and stakeholders to explore opportunities in this fast-growing sector.
“Today’s travellers seek more than leisure; they are searching for experiences that enhance their physical, mental, and emotional well-being,” said Minister Bartlett, who delivered the keynote address virtually. “Jamaica is uniquely positioned to meet this growing demand.”
He highlighted Jamaica’s abundant natural resources as a competitive edge, including over 100 rivers, 334 medicinal plants, nearly 700 miles of coastline, and mountains soaring beyond 7,000 feet. These natural assets, he stated, underpin the country’s burgeoning wellness tourism offerings.
The tourism sector’s impact continues to grow, with 4.3 million visitors expected in 2024 and projected revenue of US$4.5 billion. Minister Bartlett stressed that this success is about more than just numbers:
“This isn’t just about statistics; it’s about creating a sustainable future for our communities,” he said, outlining six global trends that Jamaica intends to capitalise on: personalised wellness experiences, technology integration, nature-based health tourism, luxury medical tourism, sustainable wellness practices, and cultural immersion.
The vision for Jamaica’s health and wellness tourism was reinforced by Dr the Hon. Christopher Tufton, Minister of Health and Wellness, who delivered an impassioned address at the conference.
Dr Tufton argued that Jamaica is uniquely poised to lead the global wellness revolution, with its world-class resorts, rich cultural heritage, and unparalleled natural beauty. He also stressed the importance of integrating wellness offerings into community-based tourism, creating opportunities for visitors to engage with local culture while addressing their health and wellness needs.
To support this ambitious vision, significant investments are being made in Jamaica’s medical infrastructure. Plans include the rehabilitation of Cornwall Regional Hospital and the Western Children and Adolescent Hospital into a medical hub featuring over 800 beds and about 14 new operating theatres.
Dr Tufton also called for greater investment in education and training to solidify Jamaica’s reputation as a global wellness destination.
“I’d make a suggestion for integrating the expertise around building out wellness in the area of training for export… Jamaica’s reputation in the international space, whether represented by these products or more importantly by the people who create the products, is exceptional. I think we need to train more of them not just to offer a solution here but when they go abroad to offer that solution as ambassadors that will then eventually mean more people having an interest at home,” said Dr Tufton.
The event, organised by the Tourism Linkages Network, a division of the Tourism Enhancement Fund (TEF), aims to position Jamaica as a premier destination for health and wellness tourism. It also seeks to strengthen connections between the health and wellness industry and other sectors, particularly manufacturing and agriculture, while showcasing Jamaica’s distinctive health and wellness tourism products.

East Africa tourism devastated by the passing of Dr. Carmen Nibingira

Dr. Carmen Nibingira, a key figure in East African tourism, passed away, leaving the industry in mourning. Her pioneering work included the EA single visa and regional marketing.

News broke about the sad passing of Dr Carmen Nibingira and the Tourism Industry of East Africa have been messaging each other with shock and surprise.
“We are all devastated as East Africa tourism stakeholders” said Jacinta Nzioka who worked alongside Dr Carmen Nibingira for many years when she was at the Kenya Tourism Board.
Those who’ve been in the industry long know Dr Carmen Nibingira, pioneer CEO of the East Africa Tourism Platform. The tourism regional private sector around 2013-2016. It is during her tenure that  East Africa (EA) countries developed a joint marketing strategy, brand, EA single visa and actively marketing as one destination. She was a gentle soul, very loving, a true and dear friend of so many in the world of tourism.
When Dr Carmen Nibingira left the East Africa Tourism Platform (EATP) and relocated to Kigali, she was a consultant with Howarth, then Mastercard and still actively involved with tourism policy within the region. She is known to have been an astute reader and a respected academic. She often would write and was actively involved with tourism training in Kigali where she served as a guest lecturer and mentor. “My peer, accountability partner and dear friend” said Jacinta Nzioka of Kenya who was in tears.
Alain St.Ange, the Head of Saint Ange Tourism Consultancy and the former Seychelles Minister responsible for Tourism, Civil Aviation, Ports and Marine said that Dr Carmen Nibingira was a true believer in Africa and of its tourism industry. “I met Dr Carmen in 2016 when I was running to be Secretary General of the UNWTO and she invited me to address a tourism industry event in Kampala in Uganda and to meet the continent’s press. I did not know Dr Carmen Nibingira at that time but was impressed by her desire for Africa not to miss the opportunity to lead the UNWTO and said that it was important for Tourism Africa to know the candidates coming from the African Continent”. and added that Africa had lost a tourism leader who worked with passion and with her heart.

Will Trump Victory Affect Oil and Gas Hiring in the USA?

The recent election of Donald Trump is poised to significantly impact hiring within the U.S. oil and gas sector.

That’s what Brian Binke, the President and CEO of Michigan based the Birmingham Group, an affiliate of Sanford Rose Associates, told Rigzone when asked if the U.S. election outcome will affect oil and gas hiring in the country.

“Trump’s commitment to expanding domestic energy production through increased drilling and fracking is expected to create numerous job opportunities in exploration, production, and related services,” Binke said.

“Industry analysts anticipate that deregulation under the new administration will further stimulate employment growth in this sector,” he added.

Binke also warned, however, that “it’s important to recognize that while federal policies can influence the energy sector, market dynamics, technological advancements, and global events also play crucial roles in shaping industry trends and employment opportunities”.

Dave Mount, the President of Louisiana based OneSource Professional Search, outlined to Rigzone that Trump’s win will initially be more positive for oil and gas hiring.

“A philosophy of less onerous/more predictable regulatory environment and a more positive view on oil and gas as an economic driver, and U.S. energy independence, favors oil and gas,” Mount said.

The OneSource Professional Search President also noted, however, that increased drilling via a Trump victory may suppress oil prices from increased supply.

“[The] previous Trump administration considered lower oil/gas prices good for the overall economy and did not overtly protect downside commodity price moves in oil and gas,” he highlighted.

“Ultimately, the combination of higher and somewhat stable commodity prices and a predictable regulatory regime will determine the profitability of oil and gas projects, which drives demand for new jobs,” he added.

Mount outlined to Rigzone that a Kamala Harris victory would have “likely continue[d] or perhaps accelerate[d] climate change regulation”, which he warned would “suppress long term investment in oil and gas exploration”.

Offering his view, Clark Conine, President and Recruiting Consultant at Texas based Energy Search Associates, outlined to Rigzone that “less regulation” from Trump’s win will “help investment”.

Rigzone also asked Gladney Darroh – an energy search specialist with 47 years of experience who developed and coaches the interview methodology Winning the Offer, which earned him the ranking of #1 technical and professional recruiter in Houston for 17 consecutive years by HAAPC – if the U.S. election outcome will affect oil and gas hiring in the United States.

Answering the question, Darroh said “the election itself won’t affect oil and gas hiring” in the country. 

“The reason is because it’s an administration’s policies and practices that are actually implemented and pursued that will affect hiring, not the rhetoric of campaigns,” the founding partner and president of Texas based Piper-Morgan Associates Personnel Consultants added.

“The oil and gas industry will adjust hiring to the reality of the next four years,” he continued.

In his response, Darroh outlined that he expects “impact will be to the upside” with Trump’s election victory.

According to the Texas Producers and Royalty Owners Association’s (TIPRO) 2024 state of energy report, which was released earlier this year, the U.S. oil and gas industry employed 2,043,855 professionals in 2023. The report highlighted that this figure represented a net increase of 56,373 direct jobs compared to 2022, “subject to revisions”.

“When incorporating direct, indirect, and induced multipliers for employment at the national level, the industry supported more than 24 million jobs last year,” the report noted.

“There were 385,662 direct U.S. upstream sector jobs in 2023, a net increase of 23,709 jobs compared to 2022,” it added.

The U.S. election took place on November 5. Trump won this election with 312 electoral votes to Kamala Harris’ 226, RealClearPolitics and 270towin, which both describe themselves as non-partisan, show. The total number of electoral votes is 538, with a minimum of 270 needed for a majority, the National Archives and Records Administration (NARA) website outlines.

To contact the author, email [email protected]

Trump’s anti-science appointees ‘drive demonisation of scholars’

Researchers who have stood up against vaccine scepticism are likely to face increased threats as Donald Trump appoints “anti-science” figures to his administration, experts have warned.Since Mr Trump was elected US president on 5 November, high-profile scientists have been deluged with abuse on social media, most notably with renewed calls for Anthony Fauci, America’s former public health chief, to be prosecuted and “held responsible” for his advice during the pandemic.
There are concerns that the appointments of Robert F. Kennedy Jr – who has repeatedly made false claims about vaccines, autism and Covid, and has been picked as health secretary – and Elon Musk, another vaccine sceptic who is leading on government efficiency, may embolden anti-vaxxers, including in Congress.
Peter Hotez, the creator of a low-cost Covid jab and a target for anti-vaxxers for many years, has experienced an uptick in online abuse since Mr Trump’s victory, but the Baylor University biologist told Times Higher Education that he saw recent events as “mostly just more of the same”.ADVERTISEMENT
He was worried, however, that the “politically motivated anti-vaccine movement” that saw “200,000 Americans needlessly perish because they refused a Covid vaccine” was “extending to childhood immunisations”.
Dean Baker, a senior economist at the Center for Economic and Policy Research, believed the elevation of anti-vaxxers to government was deeply concerning because it would be seen to validate the views of those who have threatened Professor Hotez and other experts.ADVERTISEMENT
The threats against Professor Hotez from politicians have mostly amounted to “harassment thus far demanding correspondence and requiring him to testify before Congress”, but the anti-scientist sentiment stoked in Washington could have more serious consequences, Dr Baker continued.
Along with other scientists, Professor Hotez would be “worried that he will face a situation where the full fury of the anti-vaxxers is unleashed with no one in a position of authority prepared to stand up for him or for modern medicine and science more generally”.
“To be clear, there is corruption in the system – the opioid epidemic is the most visible evidence – but these [anti-vaccine] people are not interested in cleaning up corruption. They are interested in tearing down a system that has led to longer, better lives for billions of people,” said Dr Baker.
While Professor Hotez has called for scientists to receive “better support from the societies, college presidents [and] elected leaders who care”, Mr Trump’s explicit threat to tax university endowments and to fine institutions perceived to be pursuing “woke” agendas might make this support much harder to come by than it was in 2016, one university dean told THE.ADVERTISEMENT
Her institution was already monitoring internal correspondence given the “concern that whatever we circulate publicly could be used against the college at some point down the line”, said the school leader, who asked not to be named.
“There is a real concern about the censorship of any research and teaching engaged with issues that are out of alignment with the incoming government’s ideology,” she continued.
“It certainly seems likely that federal funds might be withheld if a college or university continues to offer degrees in gender studies, African American studies, etc. This is not 2016 – no one is in the streets protesting.”
[email protected]

Trump’s anti-science appointees ‘drive demonisation of scholars’

Researchers who have stood up against vaccine scepticism are likely to face increased threats as Donald Trump appoints “anti-science” figures to his administration, experts have warned.Since Mr Trump was elected US president on 5 November, high-profile scientists have been deluged with abuse on social media, most notably with renewed calls for Anthony Fauci, America’s former public health chief, to be prosecuted and “held responsible” for his advice during the pandemic.
There are concerns that the appointments of Robert F. Kennedy Jr – who has repeatedly made false claims about vaccines, autism and Covid, and has been picked as health secretary – and Elon Musk, another vaccine sceptic who is leading on government efficiency, may embolden anti-vaxxers, including in Congress.
Peter Hotez, the creator of a low-cost Covid jab and a target for anti-vaxxers for many years, has experienced an uptick in online abuse since Mr Trump’s victory, but the Baylor University biologist told Times Higher Education that he saw recent events as “mostly just more of the same”.ADVERTISEMENT
He was worried, however, that the “politically motivated anti-vaccine movement” that saw “200,000 Americans needlessly perish because they refused a Covid vaccine” was “extending to childhood immunisations”.
Dean Baker, a senior economist at the Center for Economic and Policy Research, believed the elevation of anti-vaxxers to government was deeply concerning because it would be seen to validate the views of those who have threatened Professor Hotez and other experts.ADVERTISEMENT
The threats against Professor Hotez from politicians have mostly amounted to “harassment thus far demanding correspondence and requiring him to testify before Congress”, but the anti-scientist sentiment stoked in Washington could have more serious consequences, Dr Baker continued.
Along with other scientists, Professor Hotez would be “worried that he will face a situation where the full fury of the anti-vaxxers is unleashed with no one in a position of authority prepared to stand up for him or for modern medicine and science more generally”.
“To be clear, there is corruption in the system – the opioid epidemic is the most visible evidence – but these [anti-vaccine] people are not interested in cleaning up corruption. They are interested in tearing down a system that has led to longer, better lives for billions of people,” said Dr Baker.
While Professor Hotez has called for scientists to receive “better support from the societies, college presidents [and] elected leaders who care”, Mr Trump’s explicit threat to tax university endowments and to fine institutions perceived to be pursuing “woke” agendas might make this support much harder to come by than it was in 2016, one university dean told THE.ADVERTISEMENT
Her institution was already monitoring internal correspondence given the “concern that whatever we circulate publicly could be used against the college at some point down the line”, said the school leader, who asked not to be named.
“There is a real concern about the censorship of any research and teaching engaged with issues that are out of alignment with the incoming government’s ideology,” she continued.
“It certainly seems likely that federal funds might be withheld if a college or university continues to offer degrees in gender studies, African American studies, etc. This is not 2016 – no one is in the streets protesting.”
[email protected]